Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

Immuno-Predictor

Financiado

Mechanical Biomarkers for Prediction of Cancer Immunotherapy

Immunotherapy has revolutionized the treatment of multiple cancers and has already become a standard of care for some tumor types. However, a majority of patients do not benefit from current immunotherapeutics and many develop sev... ver más

31/03/2025

UCY

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

UNIVERSITY OF CYPRUS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-03-16

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2019-COG: ERC Consolidator Grant

I+D

Cerrada hace 5 años

0% 100% 100%

2 Participantes

UCY

2.00M€ | Lider

LM MACHINES

215.80K€ | Participante

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 60 meses Fecha Inicio: 2020-03-16
Fecha Fin: 2025-03-31

Líder del proyecto

UNIVERSITY OF CYPRUS

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto Immunotherapy has revolutionized the treatment of multiple cancers and has already become a standard of care for some tumor types. However, a majority of patients do not benefit from current immunotherapeutics and many develop severe toxicities. Therefore, the identification of biomarkers to classify patients as likely responders or nonresponders to immunotherapy is a timely and of tremendous impact task. My hypothesis is that biomechanical aspects of the tumor microenvironment mediate resistance to immunotherapy. Specifically, many tumors stiffen as they grow and also, tumor growth within the host tissue generates mechanical forces, termed solid stress. Tumor stiffening and solid stress are distinct mechanical abnormalities that compress intratumoral blood vessels, causing hypo-perfusion and hypoxia. Systemic administration of immunotherapeutics requires a well-perfused vasculature, whereas hypo-perfusion and hypoxia promote immunosuppression, helping cancer cells to evade immune responses. The objective of the proposed research is the identification of novel Mechanical Biomarkers related to tumor stiffness, solid stress, perfusion and hypoxia for prediction of immunotherapy. Tumor-bearing mice will be developed and treated with immunotherapeutic drugs and clinically used methods will be combined with computational biomechanical modeling for measuring the Mechanical Biomarkers, making the research transferable to the clinic. The biomarkers will be benchmarked against tumor normalization strategies aiming to restore/normalize mechanical abnormalities and optimize immunotherapy. Finally, the clinical utility of the selected biomarkers will be evaluated in human tumors. Only few tumor-specific biomarkers are used in the clinic - based mainly on genomic analysis. This project is expected to lead to the first biomarkers for immunotherapy prediction exploiting tumor mechanics.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores